skip to main |
skip to sidebar
Blog Archive
-
▼
2008
(233)
-
▼
February
(16)
- DiaMedica, DM-99 Shown to Improve Glucose Metaboli...
- Bentley Pharmaceuticals, Phase II India clinical s...
- Zealand Pharma, Phase III program for AVE0010/ZP10
- ConjuChem, Phase II Study of PC-DACTM:Exendin-4
- InteKrin Therapeutics' INT131, Phase IIb study in ...
- Lilly , KwikPen for Humalog and Humalog Mixtures
- Kinetic Concepts, V.A.C.Therapy to be More Efficac...
- t+ Medical, Alliance with Lifescan, Inc. to improv...
- Lipomics Technologies, Insulin Resistance Research...
- Biovail , Canadian Commercial Availability of 1,00...
- Geron, Second U.S. Patent for Production of Pancre...
- DiaKine Therapeutics’ Anti-Inflammatory Drugs
- Healthcare Providers Direct, First Accurate and Ef...
- Novagali Pharma, FDA Clearance of IND for US Clini...
- Immunosyn, First Phase “Proof of Concept Trial” in...
- Genaera, Diabetes IND In Effect for Trodusquemine ...
InteKrin Therapeutics' INT131, Phase IIb study in Type 2 diabetes
February 25, 2008—InteKrin Therapeutics, Inc., a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease, announced that it has initiated a Phase 2b study in diabetic patients with its lead product candidate INT131, a non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator)...InteKrin Therapeutics' Press Release-
February 25, 2008—InteKrin Therapeutics, Inc., a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease, announced that it has initiated a Phase 2b study in diabetic patients with its lead product candidate INT131, a non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator)...InteKrin Therapeutics' Press Release-
